ArticleFrontiers in endocrinology2025
The metabolic effect of combined liraglutide treatment and lifestyle modification on obese adolescents in a tertiary center, Riyadh.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic review of influence of ethnicity on efficacy and safety of pharmacotherapy for childhood and adolescent obesity.Clinical and experimental pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity has increased in adolescents with a rising incidence of metabolic consequences, including type 2 diabetes, necessitating new pharmacotherapeutic approaches. Liraglutide is the first FDA-approved therapy for obesity in adolescents in less than a decade. We assessed its efficacy combined with lifestyle interventions in our patients. Methods: A retrospective cohort study was conducted at a specialized children hospital in Riyadh (2019-2022). All patients had simple, non-syndromic obesity and received intensive education on lifestyle modification. Data was collected from patients in two groups: Lifestyle modification (LifeSG) Vs Lifestyle and Liraglutide (LiraglG). Comparisons of two repeated measures obtained at T1 (baseline) and T2 (6-9 months) or T3 (9-12 months), including changes in body mass index (BMI), glycated hemoglobin (HbA1c) and other metabolic markers, were performed in the two matched groups using paired t-tests. Regression analysis using linear mixed models (SAS 9.4) were used to assess the effect of treatment status over time (P-value ≤ 0.05). Results: Data collected from 138 patients (n=69 in each group) with mean BMI and HbA1c of 35.78 kg/m Conclusion: Liraglutide combined with lifestyle intervention is effective in treating obese Saudi adolescents, especially in the first 6-9 months. Continuous lifestyle intervention plays a key role in sustainability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.